Bivigou-Mboumba Berthold, Amougou-Atsama Marie, Zoa-Assoumou Samira, M'boyis Kamdem Hervé, Nzengui-Nzengui Guy Francis, Ndojyi-Mbiguino Angélique, Njouom Richard, François-Souquière Sandrine
Unité Mixte de Recherches VIH et Maladies Infectieuses Associées (UMR VIH-MIA), Centre International de Recherches Médicales (CIRMF), Libreville, Gabon.
Laboratoire de Bactériologie-Virologie, Laboratoire de Référence IST-SIDA, Université des Sciences de la Santé, Owendo, Gabon.
PLoS One. 2018 Jan 9;13(1):e0190592. doi: 10.1371/journal.pone.0190592. eCollection 2018.
In Gabon, a central African country, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are endemic. In a recent study, conducted in a semi-urban area (Franceville, Gabon), HBV infection was found to be more prevalent among HIV infected individuals. This study aims to investigate the prevalence and genetic diversity of hepatitis B virus infection among HIV infected individuals, predominantly under antiretroviral therapy, living in fully urbanized area: Libreville, capital of Gabon. Serological and molecular tests were performed to detect HBV infection among patients living with HIV/AIDS (PLHA). We used Monolisa HBsAg ULTRA, Anti-HBc Plus and Anti-HBs Plus EIA kits for serological analyses. HBV DNA viral load (HBV DNA VL) was determined by real time PCR and molecular characterization of HBV strains was performed by sequencing and phylogenetic analysis of partial HBV surface and core genes. At all, 70.2% of patients were under antiretroviral therapy. The prevalence of HBsAg was 8.8% (43/487). Detectable HBV DNA was found in 69.7% (30/43) of HBsAg positive patients and in 17.5% (24/137) HBsAg negative patients. HBV DNA VL was significantly higher among patient with CD4 cell counts less than 200 cells/mm3 than those with CD4 cell counts greater than 500 cells/mm3 (p = 0.008). We confirmed the presence of HBV sub-genotypes QS-A3 (40%), and A4 (20%) and HBV-E genotype (40%). The percentage of resistance to Lamivudine was high (40%) and varied according to the M204V/I motif. Occult hepatitis B infection (OBI) was found in patients with isolated HBcAb and among patients who had completed their HBsAg seroconversion. We detected HBV DNA for one patient without any HBV serological marker. This study provides a new landmark for the comprehension of HBV infection in PLHA in urban areas. OBI enhances HBV DNA prevalence and should be investigated in all HBsAg negative individuals.
在中非国家加蓬,人类免疫缺陷病毒(HIV)和乙型肝炎病毒(HBV)呈地方性流行。在最近一项于半城市地区(加蓬的弗朗斯维尔)开展的研究中,发现HBV感染在HIV感染者中更为普遍。本研究旨在调查居住在加蓬首都利伯维尔这一完全城市化地区、主要接受抗逆转录病毒治疗的HIV感染者中乙型肝炎病毒感染的患病率和基因多样性。对HIV/AIDS患者(PLHA)进行了血清学和分子检测以检测HBV感染。我们使用了莫诺丽莎HBsAg ULTRA、抗-HBc Plus和抗-HBs Plus酶免疫分析试剂盒进行血清学分析。通过实时PCR测定HBV DNA病毒载量(HBV DNA VL),并通过对部分HBV表面和核心基因进行测序及系统发育分析来进行HBV毒株的分子特征鉴定。总体而言,70.2%的患者正在接受抗逆转录病毒治疗。HBsAg的患病率为8.8%(43/487)。在69.7%(30/43)的HBsAg阳性患者和17.5%(24/137)的HBsAg阴性患者中检测到可检测的HBV DNA。CD4细胞计数低于200个细胞/mm³的患者的HBV DNA VL显著高于CD4细胞计数大于500个细胞/mm³的患者(p = 0.008)。我们确认了HBV亚基因型QS-A3(40%)、A4(20%)和HBV-E基因型(40%)的存在。对拉米夫定的耐药率很高(40%),并且根据M20 IV/I基序而有所不同。在单独抗-HBc阳性的患者以及已完成HBsAg血清学转换的患者中发现了隐匿性乙型肝炎感染(OBI)。我们在一名没有任何HBV血清学标志物的患者中检测到了HBV DNA。本研究为理解城市地区PLHA中的HBV感染提供了一个新的标杆。OBI增加了HBV DNA的患病率,应对所有HBsAg阴性个体进行调查。